Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications: A position statement of the Italian Society of Diabetology

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 27, Issue 2, 2017, Pages 99-114

  Buzzetti, R ^a   Prudente, S ^b   Copetti, M ^b   Dauriz, M ^c   Zampetti, S ^a   Garofolo, M ^d   Penno, G ^d   Trischitta, V ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Genetic prediction; Molecular medicine; Precision medicine

Indexed keywords

AUTOANTIBODY; HLA DQB1 ANTIGEN; HLA DR4 ANTIGEN; HLA DRB1 ANTIGEN; GENETIC MARKER; HLA ANTIGEN;

ALBUMINURIA; CLINICAL PRACTICE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEASUREMENT ACCURACY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; AREA UNDER THE CURVE; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; PEDIGREE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

AREA UNDER CURVE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GENE-ENVIRONMENT INTERACTION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEREDITY; HLA ANTIGENS; HUMANS; PEDIGREE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE;

EID: 85008440055     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.08.005     Document Type: Review

References (152)

1. [1] Emerging Risk Factors C, Sarwar, N., Gao, P., Seshasai, S.R., Gobin, R., Kaptoge, S., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
2. [2] Nokoff, N., Rewers, M., Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann NY Acad Sci 1281 (2013), 1–15.
3. [3] Replication DIG, Meta-analysis C, Asian Genetic Epidemiology Network Type 2 Diabetes C, South Asian Type 2 Diabetes C, Mexican American Type 2 Diabetes C, Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples C, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 46 (2014), 234–244.
4. [4] Altman, D.G., Bland, J.M., Diagnostic tests. 1: sensitivity and specificity. BMJ, 308, 1994, 1552.
5. [5] Altman, D.G., Bland, J.M., Diagnostic tests 2: predictive values. BMJ, 309, 1994, 102.
6. [6] Deeks, J.J., Altman, D.G., Diagnostic tests 4: likelihood ratios. BMJ 329 (2004), 168–169.
7. [7] Altman, D.G., Bland, J.M., Diagnostic tests 3: receiver operating characteristic plots. BMJ, 309, 1994, 188.
8. [8] Cook, N.R., Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 (2007), 928–935.
9. [9] Uno, H., Cai, T., Pencina, M.J., D'Agostino, R.B., Wei, L.J., On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 30 (2011), 1105–1117.
10. [10] Steyerberg, E.W., Vickers, A.J., Cook, N.R., Gerds, T., Gonen, M., Obuchowski, N., et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21 (2010), 128–138.
11. [11] Pencina, M.J., D'Agostino, R.B. Sr., D'Agostino, R.B. Jr., Vasan, R.S., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172 discussion 207–12.
12. [12] Pencina, M.J., D'Agostino, R.B. Sr., Steyerberg, E.W., Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30 (2011), 11–21.
13. [13] Kerr, K.F., Bansal, A., Pepe, M.S., Further insight into the incremental value of new markers: the interpretation of performance measures and the importance of clinical context. Am J Epidemiol 176 (2012), 482–487.
14. [14] Cook, N.R., Clinically relevant measures of fit? A note of caution. Am J Epidemiol 176 (2012), 488–491.
15. [15] Karvonen, M., Viik-Kajander, M., Moltchanova, E., Libman, I., LaPorte, R., Tuomilehto, J., Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23 (2000), 1516–1526.
16. [16] Bonifacio, E., Ziegler, A.G., Advances in the prediction and natural history of type 1 diabetes. Endocrinol Metab Clin North Am 39 (2010), 513–525.
17. [17] Eisenbarth, G.S., Banting lecture 2009: an unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 59 (2010), 759–774.
18. [18] Singal, D.P., Blajchman, M.A., Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes 22 (1973), 429–432.
19. [19] Notkins, A.L., Immunologic and genetic factors in type 1 diabetes. J Biol Chem 277 (2002), 43545–43548.
20. [20] Erlich, H., Valdes, A.M., Noble, J., Carlson, J.A., Varney, M., Concannon, P., et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57 (2008), 1084–1092.
21. [21] Buzzetti, R., Galgani, A., Petrone, A., Del Buono, M.L., Erlich, H.A., Bugawan, T.L., et al. Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease (the DIABFIN study). Diabetes Metab Res Rev 20 (2004), 137–143.
22. [22] Noble, J.A., Valdes, A.M., Cook, M., Klitz, W., Thomson, G., Erlich, H.A., The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Human Genet 59 (1996), 1134–1148.
23. [23] Rewers, M., Bugawan, T.L., Norris, J.M., Blair, A., Beaty, B., Hoffman, M., et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 39 (1996), 807–812.
24. [24] Nejentsev, S., Howson, J.M., Walker, N.M., Szeszko, J., Field, S.F., Stevens, H.E., et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450 (2007), 887–892.
25. [25] Bingley, P.J., Bonifacio, E., Gale, E.A., Can we really predict IDDM?. Diabetes 42 (1993), 213–220.
26. [26] Bonifacio, E., Predicting type 1 diabetes using biomarkers. Diabetes Care 38 (2015), 989–996.
27. [27] Lambert, A.P., Gillespie, K.M., Thomson, G., Cordell, H.J., Todd, J.A., Gale, E.A., et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89 (2004), 4037–4043.
28. [28] Redondo, M.J., Jeffrey, J., Fain, P.R., Eisenbarth, G.S., Orban, T., Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 359 (2008), 2849–2850.
29. [29] Todd, J.A., Walker, N.M., Cooper, J.D., Smyth, D.J., Downes, K., Plagnol, V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39 (2007), 857–864.
30. [30] Bjornvold, M., Undlien, D.E., Joner, G., Dahl-Jorgensen, K., Njolstad, P.R., Akselsen, H.E., et al. Joint effects of HLA, INS, PTPN22 and CTLA4 genes on the risk of type 1 diabetes. Diabetologia 51 (2008), 589–596.
31. [31] Bakay, M., Pandey, R., Hakonarson, H., Genes involved in type 1 diabetes: an update. Genes 4 (2013), 499–521.
32. [32] Noble, J.A., Valdes, A.M., Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diabetes Rep 11 (2011), 533–542.
33. [33] Kupila, A., Muona, P., Simell, T., Arvilommi, P., Savolainen, H., Hamalainen, A.M., et al. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 44 (2001), 290–297.
34. [34] Bonifacio, E., Genovese, S., Braghi, S., Bazzigaluppi, E., Lampasona, V., Bingley, P.J., et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38 (1995), 816–822.
35. [35] Verge, C.F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Jackson, R.A., et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45 (1996), 926–933.
36. [36] Kulmala, P., Savola, K., Petersen, J.S., Vahasalo, P., Karjalainen, J., Lopponen, T., et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Investig 101 (1998), 327–336.
37. [37] Veijola, R., Reijonen, H., Vahasalo, P., Sabbah, E., Kulmala, P., Ilonen, J., et al. HLA-DQB1-defined genetic susceptibility, beta cell autoimmunity, and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. J Clin Investig 98 (1996), 2489–2495.
38. [38] Knip, M., Korhonen, S., Kulmala, P., Veijola, R., Reunanen, A., Raitakari, O.T., et al. Prediction of type 1 diabetes in the general population. Diabetes Care 33 (2010), 1206–1212.
39. [39] Ziegler, A.G., Nepom, G.T., Prediction and pathogenesis in type 1 diabetes. Immunity 32 (2010), 468–478.
40. [40] Barker, J.M., Barriga, K.J., Yu, L., Miao, D., Erlich, H.A., Norris, J.M., et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89 (2004), 3896–3902.
41. [41] Ziegler, A.G., Hummel, M., Schenker, M., Bonifacio, E., Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48 (1999), 460–468.
42. [42] Nejentsev, S., Sjoroos, M., Soukka, T., Knip, M., Simell, O., Lovgren, T., et al. Population-based genetic screening for the estimation of Type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med J Br Diabetic Assoc 16 (1999), 985–992.
43. [43] Ziegler, A.G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309 (2013), 2473–2479.
44. [44] Hahl, J., Simell, T., Ilonen, J., Knip, M., Simell, O., Costs of predicting IDDM. Diabetologia 41 (1998), 79–85.
45. [45] Sabbah, E., Savola, K., Ebeling, T., Kulmala, P., Vahasalo, P., Ilonen, J., et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23 (2000), 1326–1332.
46. [46] Oram, R.A., Patel, K., Hill, A., Shields, B., McDonald, T.J., Jones, A., et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 39 (2016), 337–344.
47. [47] Erlich, H.A., Valdes, A.M., Noble, J.A., Prediction of type 1 diabetes. Diabetes 62 (2013), 1020–1021.
48. [48] Knip, M., Kukko, M., Kulmala, P., Veijola, R., Simell, O., Akerblom, H.K., et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet 115 (2002), 48–54.
49. [49] Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
50. [50] Tuomilehto, J., Lindstrom, J., Eriksson, J.G., Valle, T.T., Hamalainen, H., Ilanne-Parikka, P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001), 1343–1350.
51. [51] Uusitupa, M.I., Stancakova, A., Peltonen, M., Eriksson, J.G., Lindstrom, J., Aunola, S., et al. Impact of positive family history and genetic risk variants on the incidence of diabetes: the Finnish Diabetes Prevention Study. Diabetes Care 34 (2011), 418–423.
52. [52] Kaprio, J., Tuomilehto, J., Koskenvuo, M., Romanov, K., Reunanen, A., Eriksson, J., et al. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 35 (1992), 1060–1067.
53. [53] Groop, L., Forsblom, C., Lehtovirta, M., Tuomi, T., Karanko, S., Nissen, M., et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45 (1996), 1585–1593.
54. [54] Prasad, R.B., Groop, L., Genetics of type 2 diabetes-pitfalls and possibilities. Genes 6 (2015), 87–123.
55. [55] Hivert, M.F., Vassy, J.L., Meigs, J.B., Susceptibility to type 2 diabetes mellitus–from genes to prevention. Nat Rev Endocrinol 10 (2014), 198–205.
56. [56] McCarthy, M.I., Genomics, type 2 diabetes, and obesity. N Engl J Med 363 (2010), 2339–2350.
57. [57] Meigs, J.B., Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care 33 (2010), 1865–1871.
58. [58] Noble, D., Mathur, R., Dent, T., Meads, C., Greenhalgh, T., Risk models and scores for type 2 diabetes: systematic review. BMJ, 343, 2011, d7163.
59. [59] Chen, L., Magliano, D.J., Balkau, B., Colagiuri, S., Zimmet, P.Z., Tonkin, A.M., et al. AUSDRISK: an Australian type 2 diabetes risk assessment tool based on demographic, lifestyle and simple anthropometric measures. Med J Aust 192 (2010), 197–202.
60. [60] Hippisley-Cox, J., Coupland, C., Robson, J., Sheikh, A., Brindle, P., Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ, 338, 2009, b880.
61. [61] Lindstrom, J., Tuomilehto, J., The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26 (2003), 725–731.
62. [62] Rahman, M., Simmons, R.K., Harding, A.H., Wareham, N.J., Griffin, S.J., A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study. Fam Pract 25 (2008), 191–196.
63. [63] Schmidt, M.I., Duncan, B.B., Bang, H., Pankow, J.S., Ballantyne, C.M., Golden, S.H., et al. Identifying individuals at high risk for diabetes: the atherosclerosis risk in communities study. Diabetes Care 28 (2005), 2013–2018.
64. [64] Stern, M.P., Williams, K., Haffner, S.M., Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?. Ann Intern Med 136 (2002), 575–581.
65. [65] Wilson, P.W., Meigs, J.B., Sullivan, L., Fox, C.S., Nathan, D.M., D'Agostino, R.B., Sr, Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167 (2007), 1068–1074.
66. [66] Diabetes Genetics Initiative of Broad Institute of H, Mit, L.U., Novartis Institutes of BioMedical R, Saxena, R., Voight, B.F., Lyssenko, V., et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316 (2007), 1331–1336.
67. [67] Anand, S.S., Meyre, D., Pare, G., Bailey, S.D., Xie, C., Zhang, X., et al. Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. Diabetes Care 36 (2013), 2836–2842.
68. [68] de Miguel-Yanes, J.M., Shrader, P., Pencina, M.J., Fox, C.S., Manning, A.K., Grant, R.W., et al. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 34 (2011), 121–125.
69. [69] Imamura, M., Shigemizu, D., Tsunoda, T., Iwata, M., Maegawa, H., Watada, H., et al. Assessing the clinical utility of a genetic risk score constructed using 49 susceptibility alleles for type 2 diabetes in a Japanese population. J Clin Endocrinol Metab 98 (2013), E1667–E1673.
70. [70] Meigs, J.B., Shrader, P., Sullivan, L.M., McAteer, J.B., Fox, C.S., Dupuis, J., et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 359 (2008), 2208–2219.
71. [71] Schmid, R., Vollenweider, P., Bastardot, F., Vaucher, J., Waeber, G., Marques-Vidal, P., Current genetic data do not improve the prediction of type 2 diabetes mellitus: the CoLaus study. J Clin Endocrinol Metab 97 (2012), E1338–E1341.
72. [72] Talmud, P.J., Cooper, J.A., Morris, R.W., Dudbridge, F., Shah, T., Engmann, J., et al. Sixty-five common genetic variants and prediction of type 2 diabetes. Diabetes 64 (2015), 1830–1840.
73. [73] Talmud, P.J., Hingorani, A.D., Cooper, J.A., Marmot, M.G., Brunner, E.J., Kumari, M., et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ, 340, 2010, b4838.
74. [74] Vassy, J.L., Dasmahapatra, P., Meigs, J.B., Schork, N.J., Magnussen, C.G., Chen, W., et al. Genotype prediction of adult type 2 diabetes from adolescence in a multiracial population. Pediatrics 130 (2012), e1235–e1242.
75. [75] Vassy, J.L., Hivert, M.F., Porneala, B., Dauriz, M., Florez, J.C., Dupuis, J., et al. Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes 63 (2014), 2172–2182.
76. [76] Walford, G.A., Porneala, B.C., Dauriz, M., Vassy, J.L., Cheng, S., Rhee, E.P., et al. Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care 37 (2014), 2508–2514.
77. [77] Yang, J., Zhao, J., Cumulative effect of common genetic variants predicts incident type 2 diabetes: a study of 21,183 subjects from three large prospective cohorts. Epidemiol (Sunnyvale), 1, 2011, 108.
78. [78] Muhlenbruch, K., Jeppesen, C., Joost, H.G., Boeing, H., Schulze, M.B., The value of genetic information for diabetes risk prediction – differences according to sex, age, family history and obesity. PLoS One, 8, 2013, e64307.
79. [79] Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359 (2008), 2220–2232.
80. [80] Lyssenko, V., Laakso, M., Genetic screening for the risk of type 2 diabetes: worthless or valuable?. Diabetes Care 36:Suppl. 2 (2013), S120–S126.
81. [81] Grant, R.W., Hivert, M., Pandiscio, J.C., Florez, J.C., Nathan, D.M., Meigs, J.B., The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia 52 (2009), 2299–2305.
82. [82] Muller, G., Personalized prognosis and diagnosis of type 2 diabetes–vision or fiction?. Pharmacology 85 (2010), 168–187.
83. [83] Keating, B.J., Advances in risk prediction of type 2 diabetes: integrating genetic scores with Framingham risk models. Diabetes 64 (2015), 1495–1497.
84. [84] Pawlyk, A.C., Giacomini, K.M., McKeon, C., Shuldiner, A.R., Florez, J.C., Metformin pharmacogenomics: current status and future directions. Diabetes 63 (2014), 2590–2599.
85. [85] Walford, G.A., Colomo, N., Todd, J.N., Billings, L.K., Fernandez, M., Chamarthi, B., et al. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. PLoS One, 10, 2015, e0121553.
86. [86] Farkas, D.H., Holland, C.A., Direct-to-consumer genetic testing: two sides of the coin. J Mol Diagn 11 (2009), 263–265.
87. [87] Hunter, D.J., Khoury, M.J., Drazen, J.M., Letting the genome out of the bottle–will we get our wish?. N Engl J Med 358 (2008), 105–107.
88. [88] Chang, Y.C., Chang, E.Y., Chuang, L.M., Recent progress in the genetics of diabetic microvascular complications. World J Diabetes 6 (2015), 715–725.
89. [89] Ahlqvist, E., van Zuydam, N.R., Groop, L.C., McCarthy, M.I., The genetics of diabetic complications. Nat Rev Nephrol 11 (2015), 277–287.
90. [90] Cho, H., Sobrin, L., Genetics of diabetic retinopathy. Curr Diabetes Rep, 14, 2014, 515.
91. [91] Kuo, J.Z., Wong, T.Y., Rotter, J.I., Challenges in elucidating the genetics of diabetic retinopathy. JAMA Ophthalmol 132 (2014), 96–107.
92. [92] Bjorkegren, J.L., Kovacic, J.C., Dudley, J.T., Schadt, E.E., Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Coll Cardiol 65 (2015), 830–845.
93. [93] Williams, W.W., Salem, R.M., McKnight, A.J., Sandholm, N., Forsblom, C., Taylor, A., et al. Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes 61 (2012), 2187–2194.
94. [94] Maeda, S., Kobayashi, M.A., Araki, S., Babazono, T., Freedman, B.I., Bostrom, M.A., et al. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet, 6, 2010, e1000842.
95. [95] Boger, C.A., Chen, M.H., Tin, A., Olden, M., Kottgen, A., de Boer, I.H., et al. CUBN is a gene locus for albuminuria. J Am Soc Nephrol JASN 22 (2011), 555–570.
96. [96] Bonomo, J.A., Guan, M., Ng, M.C., Palmer, N.D., Hicks, P.J., Keaton, J.M., et al. The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease. Human Mol Genet 23 (2014), 6441–6447.
97. [97] Sandholm, N., Salem, R.M., McKnight, A.J., Brennan, E.P., Forsblom, C., Isakova, T., et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS genetics, 8, 2012, e1002921.
98. [98] Sandholm, N., McKnight, A.J., Salem, R.M., Brennan, E.P., Forsblom, C., Harjutsalo, V., et al. Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes. J Am Soc Nephrol JASN 24 (2013), 1537–1543.
99. [99] Palmer, N.D., McDonough, C.W., Hicks, P.J., Roh, B.H., Wing, M.R., An, S.S., et al. A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One, 7, 2012, e29202.
100. [100] Palmer, N.D., Ng, M.C., Hicks, P.J., Mudgal, P., Langefeld, C.D., Freedman, B.I., et al. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PLoS One, 9, 2014, e88273.
101. [101] Pezzolesi, M.G., Poznik, G.D., Mychaleckyj, J.C., Paterson, A.D., Barati, M.T., Klein, J.B., et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58 (2009), 1403–1410.
102. [102] Deshmukh, H.A., Palmer, C.N., Morris, A.D., Colhoun, H.M., Investigation of known estimated glomerular filtration rate loci in patients with type 2 diabetes. Diabet Med J Br Diabetic Assoc 30 (2013), 1230–1235.
103. [103] Shiffman, D., Pare, G., Oberbauer, R., Louie, J.Z., Rowland, C.M., Devlin, J.J., et al. A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND. PLoS One, 9, 2014, e106631.
104. [104] Leak, T.S., Perlegas, P.S., Smith, S.G., Keene, K.L., Hicks, P.J., Langefeld, C.D., et al. Variants in intron 13 of the ELMO1 gene are associated with diabetic nephropathy in African Americans. Ann Human Genet 73 (2009), 152–159.
105. [105] Cooke, J.N., Bostrom, M.A., Hicks, P.J., Ng, M.C., Hellwege, J.N., Comeau, M.E., et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 27 (2012), 1505–1511.
106. [106] Germain, M., Pezzolesi, M.G., Sandholm, N., McKnight, A.J., Susztak, K., Lajer, M., et al. SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. Diabetologia 58 (2015), 543–548.
107. [107] Swan, E.J., Salem, R.M., Sandholm, N., Tarnow, L., Rossing, P., Lajer, M., et al. Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. Diabet Med J Br Diabet Assoc 32 (2015), 1104–1109.
108. [108] Sandholm, N., Forsblom, C., Makinen, V.P., McKnight, A.J., Osterholm, A.M., He, B., et al. Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. Diabetologia 57 (2014), 1143–1153.
109. [109] Ahluwalia, T.S., Lindholm, E., Groop, L., Melander, O., Uromodulin gene variant is associated with type 2 diabetic nephropathy. J Hypertens 29 (2011), 1731–1734.
110. [110] Pattaro, C., Teumer, A., Gorski, M., Chu, A.Y., Li, M., Mijatovic, V., et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun, 7, 2016, 10023.
111. [111] Regele, F., Jelencsics, K., Shiffman, D., Pare, G., McQueen, M.J., Mann, J.F., et al. Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrol dial transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 30:Suppl. 4 (2015), iv26–iv34.
112. [112] Blech, I., Katzenellenbogen, M., Katzenellenbogen, A., Wainstein, J., Rubinstein, A., Harman-Boehm, I., et al. Predicting diabetic nephropathy using a multifactorial genetic model. PLoS One, 6, 2011, e18743.
113. [113] Kwak, S.H., Park, K.S., Genetic studies on diabetic microvascular complications: focusing on genome-wide association studies. Endocrinol metab 30 (2015), 147–158.
114. [114] Liu, L., Jiao, J., Wang, Y., Wu, J., Huang, D., Teng, W., et al. TGF-beta1 gene polymorphism in association with diabetic retinopathy susceptibility: a systematic review and meta-analysis. PLoS One, 9, 2014, e94160.
115. [115] Han, L., Zhang, L., Xing, W., Zhuo, R., Lin, X., Hao, Y., et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. J Diabetes Res, 2014, 2014, 805801.
116. [116] Hosseini, S.M., Boright, A.P., Sun, L., Canty, A.J., Bull, S.B., Klein, B.E., et al. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Human Genet 134 (2015), 247–257.
117. [117] Abhary, S., Hewitt, A.W., Burdon, K.P., Craig, J.E., A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 58 (2009), 2137–2147.
118. [118] Zhou, M., Zhang, P., Xu, X., Sun, X., The relationship between aldose reductase C106T polymorphism and diabetic retinopathy: an updated meta-analysis. Investig Ophthalmol Vis Sci 56 (2015), 2279–2289.
119. [119] Ding, Y., Hu, Z., Yuan, S., Xie, P., Liu, Q., Association between transcription factor 7-like 2 rs7903146 polymorphism and diabetic retinopathy in type 2 diabetes mellitus: a meta-analysis. Diabetes Vasc Dis Res 12 (2015), 436–444.
120. [120] Fu, Y.P., Hallman, D.M., Gonzalez, V.H., Klein, B.E., Klein, R., Hayes, M.G., et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr county, Texas. J Ophthalmol, 2010, 2010.
121. [121] Grassi, M.A., Tikhomirov, A., Ramalingam, S., Below, J.E., Cox, N.J., Nicolae, D.L., Genome-wide meta-analysis for severe diabetic retinopathy. Human Mol Genet 20 (2011), 2472–2481.
122. [122] Huang, Y.C., Lin, J.M., Lin, H.J., Chen, C.C., Chen, S.Y., Tsai, C.H., et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology 118 (2011), 642–648.
123. [123] Sheu, W.H., Kuo, J.Z., Lee, I.T., Hung, Y.J., Lee, W.J., Tsai, H.Y., et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Human Mol Genet 22 (2013), 3165–3173.
124. [124] Awata, T., Yamashita, H., Kurihara, S., Morita-Ohkubo, T., Miyashita, Y., Katayama, S., et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. PLoS One, 9, 2014, e111715.
125. [125] Peng, D., Wang, J., Zhang, R., Jiang, F., Tang, S., Chen, M., et al. Common variants in or near ZNRF1, COLEC12, SCYL1BP1 and API5 are associated with diabetic retinopathy in Chinese patients with type 2 diabetes. Diabetologia 58 (2015), 1231–1238.
126. [126] Burdon, K.P., Fogarty, R.D., Shen, W., Abhary, S., Kaidonis, G., Appukuttan, B., et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia 58 (2015), 2288–2297.
127. [127] Porta, M., Toppila, I., Sandholm, N., Hosseini, S.M., Forsblom, C., Hietala, K., et al. Variation in SLC19A3 and protection from microvascular damage in type 1 diabetes. Diabetes 65 (2016), 1022–1030.
128. [128] Cichosz, S.L., Johansen, M.D., Knudsen, S.T., Hansen, T.K., Hejlesen, O., A classification model for predicting eye disease in newly diagnosed people with type 2 diabetes. Diabetes Res Clin Pract 108 (2015), 210–215.
129. [129] Lund, S.H., Aspelund, T., Kirby, P., Russell, G., Einarsson, S., Palsson, O., et al. Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs. Br J Ophthalmol 100 (2016), 683–687.
130. [130] Lagani, V., Chiarugi, F., Thomson, S., Fursse, J., Lakasing, E., Jones, R.W., et al. Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data. J Diabetes complicat 29 (2015), 479–487.
131. [131] Witzel II, Jelinek, H.F., Khalaf, K., Lee, S., Khandoker, A.H., Alsafar, H., Identifying common genetic risk factors of diabetic neuropathies. Front Endocrinol, 6, 2015, 88.
132. [132] Meng, W., Deshmukh, H.A., van Zuydam, N.R., Liu, Y., Donnelly, L.A., Zhou, K., et al. A genome-wide association study suggests an association of Chr8p21.3 (GFRA2) with diabetic neuropathic pain. Eur J Pain 19 (2015), 392–399.
133. [133] Samani, N.J., Erdmann, J., Hall, A.S., Hengstenberg, C., Mangino, M., Mayer, B., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007), 443–453.
134. [134] Myocardial Infarction Genetics C, Kathiresan, S., Voight, B.F., Purcell, S., Musunuru, K., Ardissino, D., et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 41 (2009), 334–341.
135. [135] Dichgans, M., Malik, R., Konig, I.R., Rosand, J., Clarke, R., Gretarsdottir, S., et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke J Cereb Circ 45 (2014), 24–36.
136. [136] Wu, C., Gong, Y., Yuan, J., Gong, H., Zou, Y., Ge, J., Identification of shared genetic susceptibility locus for coronary artery disease, type 2 diabetes and obesity: a meta-analysis of genome-wide studies. Cardiovasc Diabetol, 11, 2012, 68.
137. [137] Jansen, H., Loley, C., Lieb, W., Pencina, M.J., Nelson, C.P., Kathiresan, S., et al. Genetic variants primarily associated with type 2 diabetes are related to coronary artery disease risk. Atherosclerosis 241 (2015), 419–426.
138. [138] Schunkert, H., Konig, I.R., Kathiresan, S., Reilly, M.P., Assimes, T.L., Holm, H., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43 (2011), 333–338.
139. [139] Coronary Artery Disease Genetics C, A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 43 (2011), 339–344.
140. [140] Consortium, C.A.D., Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T.L., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45 (2013), 25–33.
141. [141] Qi, L., Parast, L., Cai, T., Powers, C., Gervino, E.V., Hauser, T.H., et al. Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies. J Am Coll Cardiol 58 (2011), 2675–2682.
142. [142] Qi, L., Qi, Q., Prudente, S., Mendonca, C., Andreozzi, F., di Pietro, N., et al. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. JAMA 310 (2013), 821–828.
143. [143] Prudente, S., Shah, H., Bailetti, D., Pezzolesi, M., Buranasupkajorn, P., Mercuri, L., et al. Genetic variant at the GLUL locus predicts all-cause mortality in patients with type 2 diabetes. Diabetes 64 (2015), 2658–2663.
144. [144] Murabito, J.M., White, C.C., Kavousi, M., Sun, Y.V., Feitosa, M.F., Nambi, V., et al. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet 5 (2012), 100–112.
145. [145] Lindgren, A., Stroke genetics: a review and update. J Stroke 16 (2014), 114–123.
146. [146] International Stroke Genetics C, Wellcome Trust Case Control C, Bellenguez, C., Bevan, S., Gschwendtner, A., Spencer, C.C., et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 44 (2012), 328–333.
147. [147] Carty, C.L., Keene, K.L., Cheng, Y.C., Meschia, J.F., Chen, W.M., Nalls, M., et al. Meta-analysis of genome-wide association studies identifies genetic risk factors for stroke in African Americans. Stroke J Cereb Circ 46 (2015), 2063–2068.
148. [148] Yamada, Y., Matsui, K., Takeuchi, I., Fujimaki, T., Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study. Biomed Rep 3 (2015), 413–419.
149. [149] Kullo, I.J., Leeper, N.J., The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions. Circulation research 116 (2015), 1551–1560.
150. [150] Kullo, I.J., Shameer, K., Jouni, H., Lesnick, T.G., Pathak, J., Chute, C.G., et al. The ATXN2-SH2B3 locus is associated with peripheral arterial disease: an electronic medical record-based genome-wide association study. Front Genet, 5, 2014, 166.
151. [151] Prudente, S., Dallapiccola, B., Pellegrini, F., Doria, A., Trischitta, V., Genetic prediction of common diseases. Still no help for the clinical diabetologist!. Nutr Metab Cardiovasc Dis NMCD 22 (2012), 929–936.
152. [152] Buzzetti, R., Nistico, L., Osborn, J.F., Giovannini, C., Chersi, A., Sorrentino, R., HLA-DQA1 and DQB1 gene polymorphisms in type I diabetic patients from central Italy and their use for risk prediction. Diabetes 42 (1993), 1173–1178.